uniQure (NASDAQ:QURE) Cut to “Equal Weight” at Wells Fargo & Company

Wells Fargo & Company downgraded shares of uniQure (NASDAQ:QURE) from an overweight rating to an equal weight rating in a research report released on Monday morning, MarketBeat.com reports. The firm currently has $15.00 price objective on the biotechnology company’s stock, down from their prior price objective of $60.00.

Other analysts have also recently issued reports about the stock. Chardan Capital lowered their target price on shares of uniQure from $53.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Hold” and a consensus target price of $34.33.

uniQure Trading Up 0.1%

uniQure stock opened at $9.04 on Monday. The stock has a 50-day moving average price of $22.54 and a 200 day moving average price of $29.57. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The stock has a market cap of $565.27 million, a PE ratio of -2.62 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 7.12 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Equities research analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 50,598 shares of company stock worth $1,248,588 in the last three months. 4.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. Swiss National Bank purchased a new position in shares of uniQure in the 2nd quarter valued at $1,080,000. Sanders Morris Harris LLC acquired a new stake in uniQure in the 3rd quarter valued at $5,081,000. Aberdeen Group plc increased its holdings in uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after purchasing an additional 189,029 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of uniQure in the second quarter worth about $872,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
• Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
• Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
• Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
• Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
• Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.